Posted 18 September, 2023
Neumora Therapeutics, Inc. IPO completed
IPO completed detected for ticker Nasdaq:NMRA in a 424B4 filed on 18 September, 2023.
This is an initial public offering of shares of common stock of Neumora Therapeutics, Inc.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Neumora Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.Market Cap
$232M
View Company Details
$232M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.